|
| A) | Opium | ||
| B) | Cocaine | ||
| C) | Menthol | ||
| D) | Novocaine |
| A) | ester or amide type. | ||
| B) | short- or long-lasting. | ||
| C) | first or second generation. | ||
| D) | immediate or delayed release. |
| A) | Ester-type local anesthetics have a slightly greater risk of systemic toxicity. | ||
| B) | The injectable local anesthetics commonly used in dentistry today are all classified as amides. | ||
| C) | The risk of an allergic reaction is significantly lower with ester-type local anesthetics compared with amide-types. | ||
| D) | The ability to obtain profound intraoral anesthesia is facilitated with the use of ester formulations compared with amide formulations. |
| A) | facial nerve. | ||
| B) | abducens nerve. | ||
| C) | trigeminal nerve. | ||
| D) | vestibulocochlear nerve. |
| A) | Axon | ||
| B) | Cell body | ||
| C) | Dendrites | ||
| D) | Hypothalamus |
| A) | Vasopressin | ||
| B) | Epinephrine | ||
| C) | Levonordefrin | ||
| D) | Norepinephrine |
| A) | a shorter duration. | ||
| B) | impaired ability to achieve hemostasis. | ||
| C) | increased depth and profundity of anesthesia. | ||
| D) | quicker systemic absorption of the local anesthetic. |
| A) | Unstable angina | ||
| B) | Pheochromocytoma | ||
| C) | Untreated or uncontrolled hypertension | ||
| D) | All of the above |
| A) | Procaine | ||
| B) | Articaine | ||
| C) | Lidocaine | ||
| D) | Bupivacaine |
| A) | 1 minute. | ||
| B) | 5 minutes. | ||
| C) | 10 minutes. | ||
| D) | 30 minutes. |
| A) | Procaine | ||
| B) | Articaine | ||
| C) | Lidocaine | ||
| D) | Bupivacaine |
| A) | 0.5% formulation with a 1:200,000 concentration of epinephrine. | ||
| B) | 2% formulation with a 1:50,000 concentration of epinephrine. | ||
| C) | 3% formulation without a vasoconstrictor. | ||
| D) | 4% formulation with a 1:100,000 concentration of epinephrine. |
| A) | 34 mg per appointment. | ||
| B) | 56 mg per appointment. | ||
| C) | 90 mg per appointment. | ||
| D) | 120 mg per appointment. |
| A) | 15 minutes. | ||
| B) | 1 hour. | ||
| C) | 3 hours. | ||
| D) | 6 hours. |
| A) | Articaine | ||
| B) | Prilocaine | ||
| C) | Lidocaine | ||
| D) | Bupivacaine |
| A) | Cyanosis | ||
| B) | Tachypnea | ||
| C) | Hyperactivity | ||
| D) | Excessive caries |
| A) | avoided in all cases. | ||
| B) | administered via infiltration. | ||
| C) | started at the greatest safe dose. | ||
| D) | All of the above |
| A) | 10% lidocaine patch | ||
| B) | 10% benzocaine spray | ||
| C) | 20% benzocaine gel | ||
| D) | 20% lidocaine microspheres |
| A) | Age older than 60 years | ||
| B) | Weight greater than 150 kg (330 lbs) | ||
| C) | A history of angina or myocardial infarction | ||
| D) | Concurrent use with other medications that cause vasoconstriction |
| A) | acetamidoglycine. | ||
| B) | cholamine chloride. | ||
| C) | an 8.4% sodium bicarbonate solution. | ||
| D) | citric acid and disodium hydrogen phosphate. |